| Literature DB >> 33244229 |
Xuemeng Dong1, Zehao Wu1, Xiuping Li1, Liyan Xiao1, Man Yang1,2, Yang Li1,2, Junchao Duan1,2, Zhiwei Sun1,2.
Abstract
With the increasing production and application of engineered amorphous silica nanoparticles (aSiNPs), people have more opportunities to be exposed to aSiNPs. However, the knowledge of its adverse health effects and related mechanisms is still limited, compared with the well-studied crystalline micron-sized silica. Since small differences in the physical-chemical properties of nanoparticles could cause significant differences in the toxic effect, it is important to distinguish how these variations influence the outcoming toxicity. Notably, particle size, as one of the essential characterizations of aSiNPs, is relevant to its biological activities. Thus, the aim of this systematic review was to summarize the relationship between the particle size of aSiNPs and its adverse biological effects. In order to avoid the influence of complicated in vivo experimental conditions on the toxic outcome, only in vitro toxicity studies which reported on the cytotoxic effect of different sizes aSiNPs were included. After the systematic literature retrieval, selection, and quality assessment process, 76 eligible scientific papers were finally included in this review. There were 76% of the studies that concluded a size-dependent cytotoxicity of aSiNPs, in which smaller-sized aSiNPs possessed greater toxicity. However, this trend could be modified by certain influence factors, such as the synthetic method of aSiNPs, particle aggregation state in cell culture medium, toxicity endpoint detection method, and some other experimental conditions. The effects of these influence factors on the size-dependent cytotoxicity of aSiNPs were also discussed in detail in the present review.Entities:
Keywords: cell death; cytotoxicity; influence factors; nanotoxicology; particle size; silica nanoparticles
Mesh:
Substances:
Year: 2020 PMID: 33244229 PMCID: PMC7683827 DOI: 10.2147/IJN.S276105
Source DB: PubMed Journal: Int J Nanomedicine ISSN: 1176-9114
Figure 1Flow chart of systematic selection of articles.
Quality Assessment of Included Studies
| Source | Scientific Background Described | Study Purpose Described | Study Model Justified | Study Design Described | Endpoint Specific Defined | Cell Culture Described | Statistical Method Corrects | Endpoint Measurement Described | Concentration Response Described | Result Interpreted and Discussed | Study Founded Described | Score | Study Quality |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Wottrich | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | 11 | Good |
| Lin | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | 11 | Good |
| Yu | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | 11 | Good |
| Thomassen | √ | √ | ✘ | √ | √ | √ | √ | √ | √ | √ | √ | 10 | Good |
| Park | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | 11 | Good |
| Waters | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | 11 | Good |
| Napierska | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | 11 | Good |
| Wang | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | 11 | Good |
| Morishige | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | 11 | Good |
| Ye | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | 11 | Good |
| Park | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | 11 | Good |
| Kim | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | 11 | Good |
| Yuan | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | 11 | Good |
| Akhtar | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | 11 | Good |
| Yang | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | 11 | Good |
| Ye | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | 11 | Good |
| Gonzalez | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | 11 | Good |
| Nabeshi | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | 11 | Good |
| Nabeshi | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | 11 | Good |
| Ariano | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | 11 | Good |
| Bauer | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | 11 | Good |
| Lu | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | 11 | Good |
| Li | √ | √ | ✘ | √ | √ | √ | √ | √ | √ | √ | √ | 10 | Good |
| Corbalan | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | 11 | Good |
| Wang | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | 11 | Good |
| Al-Rawi | √ | √ | √ | √ | √ | √ | √ | √ | ✘ | √ | √ | 10 | Good |
| Uboldi | √ | √ | ✘ | √ | √ | √ | √ | √ | √ | √ | √ | 10 | Good |
| Gong | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | 11 | Good |
| Napierska | √ | √ | √ | √ | √ | √ | √ | √ | ✘ | √ | √ | 10 | Good |
| Passagne | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | 11 | Good |
| Kim | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | 11 | Good |
| McCarthy | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | 11 | Good |
| Xu | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | 11 | Good |
| Gualtieri | √ | √ | ✘ | √ | √ | √ | √ | √ | √ | √ | √ | 10 | Good |
| Panas | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | 11 | Good |
| Gazzano | √ | √ | ✘ | √ | √ | √ | √ | √ | √ | √ | √ | 10 | Good |
| Stępnik | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | 11 | Good |
| Napierska | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | 11 | Good |
| Gehrke | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | 11 | Good |
| Kasper | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | 11 | Good |
| Freese | √ | √ | √ | √ | √ | √ | √ | √ | ✘ | √ | √ | 10 | Good |
| Kim | √ | √ | ✘ | √ | √ | √ | √ | √ | √ | √ | √ | 10 | Good |
| Kusaka | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | 11 | Good |
| Vo | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | 11 | Good |
| Horie | √ | √ | ✘ | √ | √ | √ | √ | √ | √ | √ | √ | 10 | Good |
| Mendoza | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | 11 | Good |
| Docter | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | 11 | Good |
| Nemmar | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | 11 | Good |
| Kojima | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | 11 | Good |
| Xue | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | 11 | Good |
| Fede | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | 11 | Good |
| Gonzalez | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | 11 | Good |
| Nagakura | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | 11 | Good |
| Tarantini | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | 11 | Good |
| Kim | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | 11 | Good |
| Tokgun | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | 11 | Good |
| Guichard | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | 11 | Good |
| Li | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | 11 | Good |
| Saikia | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | 11 | Good |
| Manganelli | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | 11 | Good |
| Nakanishi | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | 11 | Good |
| Gong | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | 11 | Good |
| Nishijima | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | 11 | Good |
| Vicente | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | 11 | Good |
| Premshekharan | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | 11 | Good |
| Liu | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | 11 | Good |
| Låg | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | 11 | Good |
| Wang | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | 11 | Good |
| Fritsch-Decker | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | 11 | Good |
| Kim | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | 11 | Good |
| Lee | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | 11 | Good |
| Kamikubo | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | 11 | Good |
| Du | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | 11 | Good |
| Li | √ | √ | √ | √ | √ | √ | √ | √ | ✘ | √ | √ | 10 | Good |
| Leibe | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | 11 | Good |
| Wang | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | 11 | Good |
Notes: √=Yes; ✘=No.
In vitro Studies on Cytotoxicity of Amorphous Silica Nanoparticles (aSiNPs) with Different Sizes
| Source | Cell Type | Particle Primary Size | Aggregates/Agglomerates | Exposure Dose | Exposure Time | Assay(s)/Method(s) | Size-dependent Cytotoxicity |
|---|---|---|---|---|---|---|---|
| Wottrich | A549 | S-60, 100 nm | – | 10–200 μg/mL | 24 h | LDH activity assay | Cytotoxicity: 60 nm >100 nm |
| Lin | A549 | 15, 46 nm | √ | 10–100 μg/mL | 24, 48, 72 h | LDH activity assay and Sulforhod amine B assay(SRB) | Not significant |
| Yu | HEL-30 cells | S-30, 48, 118, 535 nm | – | 0–200 μg/mL | 24 h | MTT assay and LDH activity assay | Cytotoxicity: 30 nm >48 nm >118 nm >535 nm |
| Thomassen | EAHY926 | Lu-11, 14, 15 nm | No substantial aggregation, except for the Ludox-Sil-15, Stober-Sil-104, Sober-Sil-18, and Lys-Sil-2 particles | 0–2000 μg/mL | 24 h | MTT assay and WST-1 assay | The smaller the particle size, the greater the cytotoxicity. |
| Park | D3 | S-10, 30, 80, 400 nm | No substantial aggregation, except for the 10 nm particles | 0.3–100 μg/mL | 24 h, 10 days | WST-1 assay | Not significant; cytotoxicity: 30 nm >10 nm>80 nm and 400 nm |
| Waters | RAW 264.7 | P-10, 50, 150, 300, 500 nm | Moderate degree of aggregation of 10-nm particles | 0–1000 μg/mL | 24 h | MTT assay | The smaller the particle size, the greater the cytotoxicity. |
| Napierska | EAHY926 | L-14,15 nm | – | 100 μg/mL | 24 h | MTT assay and LDH activity assay | The smaller the particle size, the greater the cytotoxicity. |
| Wang | HEK293 | 20, 50 nm | – | 0–1000 μg/mL | 24 h | MTT assay | Cytotoxicity: 20 nm >50 nm |
| Morishige | TPH-1 | 30, 50, 60, 300, 1000 nm | – | 100 μg/mL | 24 h | Standard methylene blue assay | Cytotoxicity: 300, 1000 nm >30, 50, 70 nm |
| Ye | H9c2(2–1) | S-21, 48 nm | – | 0.1–1.6 mg/mL | 12, 24, 36.48 h | LDH activity assay and MTT assay | Cytotoxicity: 21 nm >48 nm |
| Park | HaCaT | 7 nm | √ | 0–300 μg/mL | 48 h | MTT assay | Not significant |
| Kim | SH-SY5Y | Lu-15.3, 16.9 nm | – | 10, 100, 1000 ppm | 48 h | MTT assay | Not significant |
| Yuan | PC12 | S-20, 50, 80,140, 280, 760 nm | – | 20–2000 μg/mL | 24 h | MTT assay | Cytotoxicity: 20 nm >50 nm >80 nm >140, 280, 760 nm |
| Akhtar | A549 | S-10, 80 nm | √ | 50–400 μg/mL | 48 h | MTT assay and LDH activity assay | Not significant |
| Yang | HaCaT | 15, 30, 365 nm | – | 2.5–80 μg/mL | 24 h | CCK-8 assay and FITC apoptosis detection | Cytotoxicity: 15 nm>30 nm>365 nm |
| Ye | L-02 | 21, 48, 86 nm | – | 200–1000 μg/mL | 12, 24, 36, 48 h | MTT assay and LDH activity assay and V-FITC/PI apoptosis assay | Cytotoxicity: 21 nm >48 nm >86 nm |
| Gonzalez | A549 | S-16, 60, 104 nm | – | 10–500 mg/mL | 24 h | MTT assay | Cytotoxicity: 16 nm >60 nm >104 nm |
| Nabeshi | HaCaT | 70, 300, 1000 nm | – | 10–1250 μg/mL | 24 h | LDH activity assay | Cytotoxicity: 70 nm >300, 1000 nm |
| Nabeshi | RAW264.7 | 70, 300, 1000 nm | – | 10, 30 μg/mL | 5 days | WST-8 assay | Cytotoxicity: 70 nm > 300, 1000 nm |
| Ariano | GT1-7 | S-50, 200 nm | – | 15–292 μg/mL | 24, 72 h | Count the cell number | Cytotoxicity: 50 nm >200 nm |
| Bauer | HUVECs | S-16, 41, 80, 212, 304 nm | – | 1000, 15,000, 30,000 NP/cell | 24, 48 h | MTT assay and LDH activity assay | Cytotoxicity: 304 nm >212 nm >16, 41, 80 nm |
| Lu | HepG2 | 7, 20, 50 nm | – | 20–640 μg/mL | 48 h | MTT assay | Not significant; cytotoxicity: 20 nm >7 nm >50 nm |
| Li | HepG2 | 19, 43, 68, 498 nm | Moderate degree of aggregation of 19 nm particles | 12.5–200 μg/mL | 24 h | CCK-8 assay and LDH activity assay and annexin V-FITC/PI apoptosis assay | Cytotoxicity: 19 nm >43 nm>68 nm >498 nm |
| Corbalan | HUVECs | 10, 50, 150, 500 nm | – | 1–100 μg/mL | 3, 7, 15, 30 h | LDH activity assay | Cytotoxicity: 10 nm >50 nm >150, 500 nm |
| Wang | PC12 | 20, 50 nm | – | 0–300 μg/mL | 12, 24, 36, 48 h | MTT assay | Cytotoxicity: 20 nm >50 nm |
| Al-Rawi | HeLa | 70, 200, 500 nm | — | 50 μg/mL | 24 h | LDH activity assay and WST-1 assay | Cytotoxicity: 70 nm >200 nm, 500 nm |
| Uboldi | Balb/3T3 | 10–25, 5-30 nm | No substantial aggregation, except for the 10–25 nm and 5–30 nm particles | 1, 10, 100 μg/mL | 72 h | MTT assay | Not significant; Only 80 nm silica nanoparticles produced significant cytotoxicity. |
| Gong | HaCaT | 15, 30, 100 nm | – | 0–100 μg/mL | 24 h | CCK-8 assay | Cytotoxicity: 15 nm >30 nm >100 nm |
| Napierska | A549 | S-2, 16, 60, 104 nm | – | 5 μg/cm2 | 24 h | LDH activity assay and MTT assay | Cytotoxicity: 2 nm >16 nm >60 nm >104 nm |
| Passagne | HK-2 | 20, 100 nm | – | 5–500 μg/mL | 24, 48, 72 h | WST-1 | Cytotoxicity: 20 nm >100 nm |
| Kim | U937 | 15, 50, 100 nm | – | 0–2000 μg/mL | 24 h | CCK-8 assay | Cytotoxicity: 15 nm >50 nm >100 nm |
| McCarthy | Calu-3 | 10, 150, 500 nm | – | 0–100 μg/mL | 2, 6, 18, 24 h | MTT assay | Cytotoxicity: 10 nm >150,500 nm |
| Xu | HFL‐I | 20, 80 nm | – | 250–2000 μg/mL | 48 h | MTT assay | Cytotoxicity: 20 nm >80 nm |
| Gualtieri | BEAS-2B | 30, 50 nm | √ | 100 μg/mL | 20 h | LDH activity assay | Not significant |
| Panas | RAW264.7 | 12, 25 nm | √ | 10–200 μg/mL | 24 h | LDH activity assay and Alamar Blue assay | Cytotoxicity: 12 nm >25 nm |
| Gazzano | MH-S | Pyr-7, 40 nm | √ | 0–160 μg/cm2 | 24 h | LDH activity assay | Not significant; cytotoxicity: 7, 40 nm >1000 nm |
| Stępnik | 3T3-L1 | Lu-21, 30 nm | Partial aggregation | 40–800 μg/mL | 72 h | LDH activity assay and WST-1 assay | Cytotoxicity: 30 nm >21 nm |
| Napierska | EA.hy926 | S-16, 60 nm | – | 25–50 μg/mL | 1, 2.5, 4, 24 h | MTT assay and LDH activity assay | Cytotoxicity: 16 nm >60 nm |
| Gehrke | HT29 | 12, 40, 200 nm | No substantial aggregation, except for the 12 nm particles | 0.1–500 μg/mL | 24, 48, 72 h | SRB assay and WST-1 assay and LDH activity assay | Cytotoxicity: 12 nm >40 nm >200 nm |
| Kasper | H441 | 30, 70, 300 nm | Partly agglomerated of 30 nm particles | 6–600 μg/mL | 4 h | MTS assay and LDH activity assay | Cytotoxicity: 30 nm >70 nm >300 nm |
| Freese | HUVEC | 30, 70 nm | The 30 nm particles tended to agglomerate with time | 60–150 μg/mL | 24 h | MTS assay and LDH activity assay | Cytotoxicity: 70 nm >30 nm |
| Kim | U373MG | 20, 100 nm | – | 0–30 mg/mL | 24 h | CellTiter-Glo luminescent assay | Cytotoxicity: 20 nm >100 nm |
| Kusaka | BMDMs | 30, 100, 300, 1000, 3000, 10,000 nm | – | 0.03–0.3 mg/mL | 2 h | LDH activity assay | Cytotoxicity 30, 100, 300 nm> |
| Vo | RTgill-W1 | S-16, 24, 44 nm | – | 1.8–1800 μg/mL | 24 h | Alamar Blue assays | Cytotoxicity: 16 nm >24 nm >44 nm |
| Horie | A549 | S-7, 25, 34 nm | √ | 10–1000 μg/mL | 24, 48 h | LDH activity assay and MTT assay | Not significant |
| Mendoza | PBMC cells | S-10, 100 nm | 10 nm particles in culture medium tend to aggregate | 50–4000 ppm | 24, 48 h | PI staining with flow cytometer | Cytotoxicity: 10 nm >100 nm |
| Docter | Caco-2 | 20, 30, 100 nm | √ | 6–600 μg/mL | 4, 24 h | MTT assay | Not significant; 30 nm silica particles produced significant cytotoxicity |
| Nemmar | HUVEC | 50, 500 nm | – | 0.1–100 μg/mL | 24 h | CellTiter-Glo® Luminescent Cell Viability Assay | Cytotoxicity: 50 nm >500 nm |
| Kojima | KUP5 | 30, 70, 300 nm | The particles of SNP70 and SNP300 appeared to be loosely aggregated in DMEM cell culture medium | 1–30 μg/cm2 | 24 h | WST-1 assay | Cytotoxicity: 30 nm >70 nm >300 nm |
| Xue | BRL | 20 nm, 0.5–6 μm | 20 nm silica nanoparticle aggregates were visible | 0.005−1 mg/mL | 18, 24 h | Thiazolyl blue tetrazolium bromide assay and LDH activity assay and MTT assay | Cytotoxicity: 20 nm >0.5–6 μm |
| Fede | A549 | Lu-9, 18 nm | – | 0.01–0.05 mg/mL | 2 h | MTS-assay | Cytotoxicity: 9 nm >18 nm |
| Gonzalez | A549 | Lys-12, 40 nm, S-28, 59, 139, 174 nm | – | 0–1056 μg/mL | 40 h | Peak flow green flow cytometry-based cytotoxicity measurement | Cytotoxicity (absence of serum): L-12 nm >L-40 nm; S-28 nm >S-59 nm >S-139 nm >S-174 nm |
| Nagakura | HaCaT | 30, 70, 300 nm | 30 nm particles approximately uniformly dispersed in the medium | 0–50 μg/cm2 | 24 h | WST-1 assay | Cytotoxicity: 30 nm >70 nm >300 nm |
| Tarantini | Caco-2 | 15, 55 nm | 15 nm particles formed aggregates | 0–256 μg/mL | 24 h | XTT assay | Cytotoxicity: 15 nm >50 nm |
| Kim | A549 | S-20, 40, 60, 80, 100, 150, 200 nm | √ | 10–500 μg/mL | 24, 72 h | LDH activity assay and MTT assay | Not significant |
| Tokgun | A549 | S-6, 15, 30, 55 nm | – | 0.1–1000 μg/mL | 72 h | CytoToxGlo kit and TUNEL analysis | Cytotoxicity: 6 nm >15 nm >30, 55 nm |
| Guichard | V79 | Pyr 20: 19±5 nm | √ | 1.25–100 μg/cm2 | 24 h | WST-1 | Cytotoxicity: Col15 >Pyr 20=Pre 20 >Pyr 25/70=Col 40/80. |
| Pyr 25/70: 71±25/25±8 nm | |||||||
| Pre 20: 19±3 nm | |||||||
| Col 15: 15±4 nm | |||||||
| Col 40/80: 79±3/38±5 nm | |||||||
| Li | BEAS-2B | S-40, 60, 200 nm | – | 6.25–100 μg/mL | 6, 12, 24 h | MTT assay and LDH activity assay | Cytotoxicity: 40 nm >60 nm >200 nm |
| Saikia | RAW 264.7 | S-50, 500 nm | – | 4–500 μg/mL | 24 h | CCK-8 assay and LDH activity assay | Cytotoxicity: 50 nm >500 nm |
| Manganelli | HEK293 | 20, 50 nm | – | 25–200 μg/mL | 12, 24, 36, 48 h | MTT assay | Cytotoxicity: 20 nm >50 nm |
| Nakanishi | mBMDCs | 30, 70, 300 nm | – | 1–20 μg/cm2 | 24 h | LDH activity assay | Cytotoxicity: 30 nm >70 nm >300 nm |
| Gong | HaCaT | 15 nm,1–5 μm | – | 0–200 μg/mL | 24 h | CCK-8 assay and LDH activity assay and MTT assay and flow cytometric analysis | Cytotoxicity: 15 nm>1–5 μm |
| Nishijima | TPH-1 | 10, 30, 50, 70, | – | 12.5–200 μg/mL | 6, 12, 24 h | LDH activity assay | Not significant |
| Vicente | K17 | Lu-20 nm | 70 nm silica nanoparticle aggregates were visible | 5–200 μg/mL | 24 h | LDH activity assay and WST-1 assay and PI staining and nuclei counting | Cytotoxicity: 20 nm >70 nm ≥200, 500 nm |
| Premshekharan | THP-1 | 50 nm, 2 μm | The particles of 2 μm appeared to be loosely aggregated in cell culture medium | 1–100 μg/mL | 22 h | MTT assay | Cytotoxicity: 50 nm >2 μm |
| Liu | A549 | 10–20 nm, 1–5 μm | – | 0–100 μg/mL | 24 h | CCK-8 assay and annexin V FITC apoptosis detection kit | Cytotoxicity: 10–20 nm >1–5 μm |
| Låg | BEAS-2B | 10, 50 nm | 10 nm particles showed polydispersity in media | 0–200 μg/mL | 20 h | LDH activity assay | Cytotoxicity: 10 nm >50 nm |
| Wang | HUVECs | S-10, 25, 50, 100 nm | A degree of aggregation of four particles | 1–25 μg/mL | 24 h | CCK-8 assay and flow cytometry assay | Cytotoxicity: 10 nm >25 nm >50 nm >100 nm |
| Fritsch-Decker | HCT116 | 12, 70, 200, 500 nm | 12 nm NPs were already aggregated to 232 nm in medium without FBS | 0–100 μg/mL | 24, 48 h | LDH activity assay and Alamar Blue assay | Cytotoxicity: 12 nm >70 nm>200, 500 nm |
| Kim | HepG2 | S-20, 30, 40, 50 nm | Particles aggregates formed in PBS solution containing FBS | 5–500 μg/mL | 24 h | WST-1 assay | Cytotoxicity: 20, 30 nm >40, 50 nm |
| Lee | HUVECs | S-20, 30, 40, 50 nm | – | 5–25 μg/mL | 24 h | FITC-annexin-V & propidium iodide (PI) assay | Cytotoxicity: 20 nm >30, 40, 50 nm |
| Kamikubo | Rat hippocampal cells | 10, 30, 100, | – | 0.0001−5 mg/mL | 2 h | CTG assay and MTT assay and propidium iodide (PI) assay | Cytotoxicity: 10 nm >30 nm>100 nm>400 nm >1500 nm |
| Du | N9 | S-50, 100, 300 nm | – | 25–200 μg/mL | 24 h | MTS assay | Cytotoxicity in N9 cells: 50 nm >100 nm >300 nm |
| Li | BEAS-2B | S-40, 60, 200 nm | – | 25 μg/mL | 24 h | CCK-8 assay | Cytotoxicity: 40 nm>60 nm>200 nm |
| Leibe | RAW 264.7 | 12, 50 nm | Large numbers of 50 nm particles agglomerates in the absence of serum | 10–100 μg/mL | 24 h | LDH activity assay and Alamar Blue assay | Cytotoxicity: 12 nm >50 nm |
| Wang | HUVECs | 20, 100 nm | – | 0–200 μg/mL | 24 h | CCK-8 assay and LDH activity assays | Cytotoxicity: 100 nm >20 nm |
Figure 2Fan-shaped diagram of the relationship between cytotoxicity of aSiNPs and its particle size.